PLoS ONE (Jan 2014)

High levels of SOX5 decrease proliferative capacity of human B cells, but permit plasmablast differentiation.

  • Mirzokhid Rakhmanov,
  • Heiko Sic,
  • Anne-Kathrin Kienzler,
  • Beate Fischer,
  • Marta Rizzi,
  • Maximilian Seidl,
  • Kerstina Melkaoui,
  • Susanne Unger,
  • Luisa Moehle,
  • Nadine E Schmit,
  • Sachin D Deshmukh,
  • Cemil Korcan Ayata,
  • Wolfgang Schuh,
  • Zhibing Zhang,
  • François-Loic Cosset,
  • Els Verhoeyen,
  • Hans-Hartmut Peter,
  • Reinhard E Voll,
  • Ulrich Salzer,
  • Hermann Eibel,
  • Klaus Warnatz

DOI
https://doi.org/10.1371/journal.pone.0100328
Journal volume & issue
Vol. 9, no. 6
p. e100328

Abstract

Read online

Currently very little is known about the differential expression and function of the transcription factor SOX5 during B cell maturation. We identified two new splice variants of SOX5 in human B cells, encoding the known L-SOX5B isoform and a new shorter isoform L-SOX5F. The SOX5 transcripts are highly expressed during late stages of B-cell differentiation, including atypical memory B cells, activated CD21low B cells and germinal center B cells of tonsils. In tonsillar sections SOX5 expression was predominantly polarized to centrocytes within the light zone. After in vitro stimulation, SOX5 expression was down-regulated during proliferation while high expression levels were permissible for plasmablast differentiation. Overexpression of L-SOX5F in human primary B lymphocytes resulted in reduced proliferation, less survival of CD138neg B cells, but comparable numbers of CD138+CD38hi plasmablasts compared to control cells. Thus, our findings describe for the first time a functional role of SOX5 during late B cell development reducing the proliferative capacity and thus potentially affecting the differentiation of B cells during the germinal center response.